FX-322 in Adults With Acquired Sensorineural Hearing Loss - Full Text View.

December 15, 2022 - Frequency Therapeutics is actively working to transform the treatment of hearing loss. Learn more about our approach to degenerative diseases.

February 13, 2023 - FX-322-208 Study Fails to Meet Primary Endpoint, Showing No Significant Separation in Speech Perception Between FX-322 and Placebo Company Will Now Focus on Advancing its Program in Remyelination for Multiple Sclerosis (MS) Announces Corporate Restructuring and Will Also Explore Strategic

profile of CV in guinea pigs, then measure FX-322 in human perilymph samples, and finally assess safety and audiometric effects of FX-322 in humans with chronic SNHL. Study Designs: Middle ear residence, cochlear distribution, and elimination profiles of FX-322 were assessed in guinea pigs.

December 12, 2022 - The 208 study was rigorously designed to ensure the stability of an individual’s hearing prior to entering the trial and to exclusively enroll those with the types hearing loss where we observed the strongest hearing improvement in prior FX-322 studies. FX-322 continues to have a favorable ...

February 14, 2023 - (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL).

February 13, 2023 - (RTTNews) - Frequency Therapeutics, Inc. (FREQ) reported clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss. The study failed to achieve its primary efficacy endpoint of an improvement in speech perception

February 14, 2023 - Shares of US regenerative medicines firm Frequency Therapeutics (Nasdaq: FREQ) plummeted more than 80% to $0.75 yesterday, after it announced it is terminating programs in sensorineural hearing loss (SNHL) because FX-322 failed to meet the goal of a study in people with acquired SNHL, and is ...

Delivery of FX-322 to the extended high-frequency region of the cochlea is well tolerated and enhances speech recognition performance in multiple subjects with stable chronic hearing loss.

October 20, 2021 - Study record managers: refer to the Data Element Definitions if submitting registration or results information

October 20, 2021 - Study record managers: refer to the Data Element Definitions if submitting registration or results information

March 8, 2023 - Frequency was testing its hearing loss therapy, FX-322, in patients who have sensorineural hearing loss (SNHL), which is caused by damage to the tiny hair cells in the ear that turn vibrations into the electrical signals sent to the brain via the auditory nerve.

May 5, 2022 - These milestones include: FX-322 Phase 2b study results in hearing restoration, which are anticipated in Q4 2022 or Q1 2023; Phase 1 study results of FX-345, our second hearing restoration program that aims to distribute drug deeper into the cochlea and potentially treat additional individuals ...

October 20, 2021 - Study record managers: refer to the Data Element Definitions if submitting registration or results information

December 16, 2022 - The double-blinded, randomised, placebo-controlled, multicentre trial is intended to assess the efficacy of FX-322 on speech perception in participants aged 18 to 65 years, with hearing loss linked to either noise-induced or permanent idiopathic sudden SNHL.

November 15, 2021 - Learn about FX-322, our product candidate designed to treat the underlying cause of acquired sensorineural hearing loss.

March 11, 2022 - Frequency Therapeutics is currently conducting a Phase 2b trial to see if a new drug candidate can restore hearing in people who experience sensorineural hearing loss (SNHL).

February 13, 2023 - FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M , Providing Runway into 2024; Funds Enable Company to Meet Multiple Clinical Milestones for Programs Targeting Hearing

November 2, 2021 - FX-322 is a new pharmaceutical research drug by Frequency Therapeutics aimed at finding a cure for hearing loss. This article will discuss updates in the drug’s development and its effectiveness in…